Curadigm, an early-stage nanotechnology company dedicated to improving treatment outcomes by shifting the therapeutic delivery paradigm, today announced the selection of its project for the Sanofi iTech Awards program with its proprietary Nanoprimer technology. The Sanofi iTech Awards program aims to identify external innovations with the potential to significantly improve drug discovery and design, drug delivery and drug development within Sanofi. […]
Curadigm today announced the receipt of 1 Million € in non-dilutive funding from Deep Tech BPI France for the development of their Nanoprimer technology. The Deep Tech program recognizes biotechnology companies with breakthrough innovation and strong commercial potential. The funding award highlights the Nanoprimer’s unique, groundbreaking approach to increasing therapeutic bioavailability and efficacy, which is applicable across multiple drug classes. […]
The data generated during this fruitful collaboration with Prof. Langer’s lab and published in Nano Letters are very important for Curadigm. it represents an external validation of our concept to address the unmet needs of nucleic acid - based therapeutics. The potential of the Nanoprimer to improve treatment efficacy by avoiding liver clearance is a great opportunity to accelerate the development of RNA-based therapeutics and to bring a real benefit for the patients. […]
The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way. Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance. This temporarily increases the therapeutic’s bioavailability and subsequent accumulation in target tissue. […]
After achieving the milestone of our first European market approval for Nanobiotix’s lead oncology product candidate, NBTXR3, our business continues to build momentum. We are thrilled to announce the launch of our subsidiary, Curadigm—another disruptive technology platform we have built as a result of pioneering nanomedicine for more than 15 years. While Nanobiotix remains focused on continued development of NBTXR3, we are pleased to open new growth pathways for our business and shareholders. […]